

BEAM ALLIANCE

Mar. 16-17
2023
Congress Center
Basel | Switzerland

7th AMR Conference

Novel Antimicrobials & AMR Diagnostics

amr-conference.com
#AMRconference

©SciePro - stock.adobe.com

Organization: bamconn GmbH I Erholungsweg 51 I 13509 Berlin
Boris Mannhardt I info@bamconn.eu I Tel. +49 (0)176 101 439 86

bamconn

SSID: **Free-Messe-Basel**

Free SMS Login (one login for each device)

About this conference

The **#AMRconference** is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss **strategies and specific challenges faced by the innovation ecosystem** in bringing new antimicrobial treatments and diagnostics to the market.

The conference is the one-stop shop to catch up with the latest trends in the development of AMR products, by covering scientific, regulatory, financial and policy topics. Besides high-level talks, the conference is a great place to network and exchange views on innovative technologies, development paths and alternative business models with your peers. The conference also offers a partnering platform to facilitate interactions.

The 7th edition will cover the whole innovation value chain, including scientific breakthrough, pre-clinical and clinical development, but also financial topics such as public funding for R&D, market incentive and investors' perspective. Specific sessions will also be dedicated to antimicrobials in the environment, diagnostics, antifungals, biologics and anti-tuberculosis drug combinations. There will also be a special focus on India and how the country is getting prepared to provide global solutions against AMR. Among other highlights are a start-up competition, hosted by the pharma-backed incubator INCATE, and a poster prize.

The AMR Conference is jointly organized by BEAM Alliance and bamconn GmbH. It was started in 2017 as part of the annual "Berlin Conference on Life Sciences" series which was established twelve years ago as an event format to discuss the challenges of SME-driven innovation for the health market and **to offer a platform for meeting experts from business, science, clinics, finance, regulatory affairs and intellectual property**.

The BEAM Alliance is one of the major supporting partners of the AMR Conference. Launched in June 2015, the BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) Alliance gathers more than 70 small and medium-sized European biotech and diagnostics companies committed to developing innovative products for fending off antibiotic-resistant pathogens. BEAM Alliance carries the voice of SMEs to support policies and incentives in antimicrobial research and development in Europe.

bamconn GmbH was established in November 2022 as a spin-off of BIOCOM AG and continues its entire event management as an independent company. It is built on more than 15 years of experience in the planning, organization and implementation of scientific events and exhibitions. The portfolio covers the entire spectrum from small workshops with 20 participants to multi-day international conferences for up to 2,000 people as well as exhibitions on the topic of bioeconomy throughout Europe. Customers for whom the bamconn team worked so far are companies, research institutions, associations and federal ministries as well as subordinate authorities and EU-funded projects.

At a glance

Conference Day 1

09:00–11:00	**General assembly BEAM Alliance** (BEAM members only) Room Kairo page 6		
11:00–11:30	Networking Break		
11:30–13:00	**Pre-conference workshop** **“Promise of artificial intelligence to antibacterial drug discovery”** Room Shanghai page 6		
13:00–18:00	**1-to-1 Partnering Meetings**		
13:00–21:30	Registration, poster presentations and exhibition open		
	Opening Session		
14:00–15:30	**Solving the AMR pandemic: where do we stand?** Room Shanghai page 6		
15:30–16:00	Coffee Break with poster session & exhibition		
16:00–17:30	**Parallel Tracks**		
	National efforts on pull incentives: latest updates Room Shanghai page 7	**Novel tools in pre-clinical development** Room Delhi page 7	**Advancing the biological pipeline against AMR pathogens** Room Kairo page 7
17:30–18:00	Coffee Break with poster session & exhibition		
18:00–19:30	**Start-up pitch** Room Shanghai page 7		
19:30–21:30	Reception in the exhibition hall		

Day 1
16 Mar.

Partnering

Meet the right people and take your business/collaboration idea, technology or R&D project to the next level.

The #AMRconference is the perfect place to meet with existing and new potential partners and investors from the AMR community in 1:1 partnering meetings.

Our online partnering tool allows you to identify potential partners and manage all your meeting requests face-to-face and virtually.

During the AMR Conference 2023 all partnering meetings will take place on-site. Therefore, we will have a designated partnering area as well as the opportunity to meet exhibitors directly at their booth.

The pre-scheduled one-to-one meetings take place as follows:

Day 1, 16 March: 13:00–18:00
Day 2, 17 March: 8:00–17:30

The length of each meeting slot is 25 minutes.

Please check your individual meeting schedule for times and locations of your confirmed meetings.

Meeting locations: Exhibition Hall

Need help? Please see the Partnering Help Desk at the registration.

Conference Day 2

08:00–18:30	Registration, poster presentations and exhibition open		
08:00–17:30	**1-to-1 Partnering Meetings**		
08:30–10:00	**Parallel Tracks**		
	How to improve the success rate of clinical trials in unmet medical needs populations? Room Shanghai page 8	**Breakthrough from early-stage research** Room Delhi page 8	**Antimicrobials in the environment: time for action** Room Kairo page 8
10:00–10:30	Coffee break with poster session & exhibition		
	Plenary Session		
10:30–12:00	**AMR India pavillion: challenges and opportunities for providing global solutions** Room Shanghai page 8		
12:00–13:30	Lunch Break with poster session & exhibition		
13:30–14:30	**Parallel Tracks**		
	Investing in AMR innovation: How to get prepared for the future and restore value creation perspectives in the field? Room Shanghai page 9	**Towards better treatment combination against tuberculosis** Room Delhi page 9	**Antifungals: back to menu** Room Kairo page 9
14:30–15:00	Networking Break in the exhibition hall		
15:00–16:00	**Parallel Tracks**		
	PUSH landscape: are all the gaps filled? Room Shanghai page 10	**Leveraging disgnosticsto improve the development and appropriate use of antimicrobials** Room Delhi page 10	**Technology update** Room Kairo page 10
16:00–16:30	Coffee break with poster session & exhibition		
	Closing Session		
16:30–17:30	**AMR to do list: homework to avoid the disaster** Room Shanghai page 10		
17:30–18:30	Farewell reception in the exhibition hall		

Pre-conference

Room Kairo

09:00–11:00 **BEAM Alliance General Assembly**
for BEAM members only

Pre-conference

Room Shanghai

11:30–13:00 Pre-conference workshop
Promise of AI to antibacterial drug discovery
jointly organized by

Introduction
***Ursula Theuretzbacher**, Center for Anti-Infective Agents, Vienna, Austria*

How predictive modeling and data analytics shifts our perspectives about drug discovery for infectious diseases
***Jitao David Zhang**, Computational biologist, F. Hoffmann-La Roche*

Drug discovery at the interface between Computer-Aided Drug Discovery, Cheminformatics and Research Informatics
***Nikolaus Stiefl**, Global Discovery Chemistry, Novartis*

AI-driven Anti-infectives - Exscientia's Approach
***Denise Barrault,** Director, Novel Technology and Biology Partnerships, Exscientia*

Discussion

Day 1
16 Mar.

Opening Session

Room Shanghai

14:00–15:30 **Solving the AMR pandemic - where do we stand?**

***Marc Gitzinger,** BioVersys AG & BEAM Alliance*

***John Alter,** AMR Action Fund*

***Rachel Silverman Bonnifield,** Center for Global Development*

***Mariano Votta,** Active Citizenship Network*

***Kristine Peers,** EFPIA*

***Wolfgang Philipp,** European Commission*

***Antoni Torres,** Hospital Clínic Barcelona*

Parallel Tracks

Room Shanghai

16:00–17:30 **National efforts on pull incentives: latest updates**

Kevin Outterson, *Boston University & CARB-X*

Senator Todd Young, *US Congress*

Tetsuya Itani, *Japanese Ministry of Health, Labout and Welfare*

Thomas Hälbig, *German Nat. Association of Statutory Health Insurance Funds*

Joel Denis, *Public Health Agency of Canada*

Rachel Silverman Bonnifield, *Center for Global Development*

Room Delhi

16:00–17:30 **Novel tools in pre-clinical development**

Pete Jackson, *Infex Therapeutics & BEAM Alliance*

Urs Jenal, *NCCR AntiResist*

Pr. Giancarlo Biagini*, iiCON*

Maria Uria-Nickelsen*, CARB-X*

Shampa Das*, Liverpool University*

Radu Botgros, *European Medicines Agency*

Rakel Arrazuria, *Paul Ehrlich Institute & AMR Accelerator*

Remko van Leeuwen, *Madam Therapeutics & BEAM Alliance*

Room Kairo

16:00–17:30 **Advancing the biological pipeline against AMR pathogens**

Bernhard Kerscher, *Paul Ehrlich Institute*

Ed Buurman, *CARB-X*

Hasan Jafri, *Aridis Pharmaceuticals*

Dominik Gary, *Research Center for Medical Technology and Biotechnology*

Jan Poolman, *Janssen Vaccines & Prevention*

Plenary Session

Room Shanghai

18:00–19:30 **Start-up pitch**

hosted by INCATE Prize Sponsor VOSSIUS

Start-ups in running order: iFast Diagnostics, MyxoBiomedical, Oxford SimCell, Spartha Medical, Betatide, AbGenics LifeSciences, Genova Therapeutics, EVIIVE, EpyNext Therapeutics, Disperazol, Fagoterapia Lab

Parallel Tracks

Room Shanghai

08:30–10:00 **How to improve the success rate of clinical trials in unmet medical needs populations?**

Glenn Dale, *BioVersys*

Marlieke de Kraker, *University of Geneva*

John Rex, *F2G*

Radu Botgros, *European Medicines Agency*

David Paterson, *National University of Singapore*

Matteo Bassetti, *University of Genoa*

Room Delhi

08:30–10:00 **Breakthrough from early-stage research**

Christoph Dehio, *NCCR AntiResist*

Zemer Gitai, *Princeton University & Arrepath*

Nassos Typas, *EMBL*

Priscille Brodin, *INSERM*

Day 2
17 Mar.

Room Kairo

08:30–10:00 **Antimicrobials in the environment: time for action**

Cees de Joncheere, *WHO*

Dominic O'Neil, *Qiagen*

Steve Brooks, *AMR Industry Alliance*

Joakim Larsson, *University of Gothenburg*

Valeria Gigante, *WHO*

Plenary Session

Room Shanghai

10:30–12:00 **AMR India pavillion: challenges and opportunities for providing global solutions**

Anand Anandkumar, *Bugworks*

Yann Ferisse, *GARDP*

Jaideep Gogtay, *CIPLA Pharma*

Taslimarif Saiyed, *Centre for Cellular and Molecular Platforms (CCAMP)*

Kamini Walia, *Indian Council of Medical Research*

Camilla Rodrigues, *Hinduja Hospital Mumbai*

Parallel Tracks

Room Shanghai

13:30–14:30 **Investing in AMR innovation: How to get prepared for the future and restore value creation perspectives in the field?**

Florence Séjourné, *AuroBac Therapeutics & BEAM Alliance*

Martin Heidecker, *AMR Action Fund*

Wolfgang Philipp, *European Commission*

Bita Sehat, *TRILL Impact*

Camilla Petrycer Hansen, *Novo REPAIR Impact Fund*

Fei Shen, *Boehringer Ingelheim Venture Fund*

Room Delhi

13:30–14:30 **Towards better treatment combination against tuberculosis**

Martin Boeree, *Radboud University*

Ainhoa Lucía Quintana, *University of Zaragoza*

Santiago Ferrer Bazaga, *ISCIII*

Samuel Schumacher, *WHO*

Norbert Heinrich, *Ludwig-Maximilians-University of Munich*

Room Kairo

13:30–14:30 **Antifungals: back to menu**

Mark Jones, *Basilea Pharmaceutica & BEAM Alliance*

Hatim Sati, *WHO*

John Rex, *F2G*

Werner Heinz, *Caritas Hospital*

Parallel Tracks

Room Shanghai

15:00–16:00 **PUSH landscape: are all the gaps filled?**

Remko van Leeuwen, *Madam Therapeutics & BEAM Alliance*

Ralf Sudbrak, *Global AMR R&D Hub*

Douglas Häggström, *INCATE*

Anders Karlén*, Uppsala University*

Su Chiang*, CARB-X*

Beverly Isherwood*, MD Catapult*

Cornelis Boersma, *Netherlands Antibiotics Development Platform*

Room Dehli

15:00–16:00 **Leveraging diagnostics to improve the development and appropriate use of antimicrobials**

Betsy Wonderly-Trainor, *CARB-X*

Amir Nakar, *MeMed*

Chantal Morel, *University of Bern*

Jeroen Nieuwland, *Llusern Scientific*

Theresa Liebe, *Blink*

Day 2
17 Mar.

Room Kairo

15:00–16:00 **Technology updates**
organized by Debiopharm

Morgane Vanbiervliet, *Debiopharm*

Natalie D'Amore, *Seres Therapeutics*

David Cameron, *Debiopharm*

Delphine Croisier, *Vivexia*

Christian Röhrig, *Micreos*

Kwangmin Son, *PhAST*

Closing Session

Room Shanghai

16:30–17:30 **AMR todo list: homework to avoid the disaster**

Deborah O'Neil, *Novabiotics & BEAM Alliance*

James Anderson, *IFPMA*

Flic Gabbay, *Transcrip*

Alexandra Cameron, *WHO*

Seamus O'Brien, *GARDP*

BEAM ALLIANCE

8th AMR Conference

Novel Antimicrobials & AMR Diagnostics

March 6-7

2024

Congress Center
Basel | Switzerland

Save the date

amr-conference.com
#AMRconference

©SciePro - stock.adobe.com

Organization: bamconn GmbH I Erholungsweg 51 I 13509 Berlin
Boris Mannhardt I info@bamconn.eu I Tel. +49 (0)176 101 439 86

bamconn

Floor Map

Venue:

Congress Center Basel
Hall 4
Messeplatz 21
4058 Basel, Switzerland



Program Rooms
Exhibitor Stands
Catering
Corporate Room Innovate UK
Partnering Area
Poster Presentation

Poster Exhibition

No.	Title	Corresponding Author
1	**Interspecies variability in antibiotics protein binding and bacterial growth in-vitro as basis for translational PK/PD studies**	**Hifza Ahmed**, Medical University Vienna
2	**AbTids: A new class of anti infective biologicals**	**Sanjiban Banerjee**, AbGenics LifeSciences
3	**A multiplex platform for the detection of antibiotic resistance**	**Julia Beck-Nafz**, GenID GmbH
4	**Diagnostic AMR innovations for humans and animals**	**Lucy Bock,** UK Health Security Agency
5	**Development of anti-virulence agents targeting HilD, the central regulator of Salmonella pathogenicity**	**Abdelhakim Boudrioua,** University of Tübingen
6	**Predicting permeabilities of small-molecules through bacterial porins: the scoring function 2.0**	**Matteo Ceccarelli,** University of Cagliari
7	**Mechanism of Action studies using systematic analysis platform**	**Jan-Martin Daniel**, University of Bonn
8	**Whole-Genome Sequencing for Genitc Characterization of Antimicrobial Resistance in Campylobacter jejuni Isolated from Turkeys in Germany**	**Hosny Hassan El Adawy,** Friedrich-Loeffler-Institut
9	**EpyNext Therapeutics**	**Louis Farge,** EpyNext Therapeutics
10	**Understanding Older People's Perceptions of Preventative and Therapeutic Diet-Related Antimicrobial Resistance Management**	**Lorna Flintham,** University of Bath
11	**Molecular characterization of more than 700 different methicillin-resistant Staphylococcus aureus clones**	**Dominik Gary,** fzmb GmbH
12	**Disperazol: treating catheter associated urinary tract biofilm infections**	**Michael Graz,** University of Copenhagen
13	**A standard protocol for the murine pneumonia model to evaluate treatments for AMR lung infections**	**Lon Ulf Hansen,** Statens Serum Institut Denmark
14	**A Vaccine Targeting Urinary Tract Infections using SimCells, Safe, genome-free, non-replicating bacteria cells with high immunogenicity**	**Jane Hsu,** Oxford SimCell Ltd.
15	**Pseudomonas aeruginosa surface attachment studies for facilitating new drug development**	**Han-Yi Huang,** EPFL Lausanne
16	**Flexible and multiplexed microfluidic cultivation platform for monitoring bacteria under drug exposure**	**Petra Jusková,** EZH Zürich
17	**Challenging molecular diagnostics with quantum mechanics – ICHORtec's FMB-technology for highly sensitive and rapid in vitro diagnostics**	**Uwe Korth,** ICHORtec

No.	Title	Corresponding Author
18	**InSignia has the capacity to shift the standard of infection diagnosis and guided therapy**	**Nicole Lima,** SpeeDx Pty Ltd
19	**Thiol oxidation and CoA depletion cause antibiotic tolerance**	**Pablo Manfredi,** Universtiy of Basel
20	**The role of macrophages and intracellular survival of Staphylococcus aureus – new insights from direct evaluation of human tissue samples**	**Benedict Mroin,** University of Basel
21	**A novel antibacterial peptide in the fight against AMR**	**Marit Otterlei,** Norwegian University of Science and Technology
22	**Pre-clinical development of Corallopyronin A – a natural product active against helminths, STIs and Staphylococci**	**Kenneth Pfarr,** University Hospital Bonn
23	**DUTI: a 15 min point-of-care test for direct urine tract infections identification**	**Giulia Pilla,** Nostics
24	**Development of Deep Learning Models for Sub-Cellular Fluctuation Imaging (SCFI): a 30-minute antibiotic susceptibility test**	**James Preece,** FluoretiQ Ltd.
25	**Rapid 15-minute test to identify the 3 most common gram-negative uropathogens in Urinary Tract Infections**	**James Preece,** FluoretiQ Ltd.
26	**Lipophosphonoxins – Novel Membrane Targeting Antimicrobial"s**	**Dominik Rejman,** Czech Academy of Sciences
27	**Design of Antimicrobial Peptides to Fight Antimicrobial Resistance**	**Niels Röckendorf,** Research Center Borstel
28	**The Fastest Antiviral & Antibacterial Technology In The World**	**Reza Saberi,** CodiKoat Ltd.
29	**Development of a Synthetic Human Urine formulation for the study of UPEC physiology and the development of antibiotics**	**Benjamin Sellner,** University of Basel
30	**Development of a Bladder Organoid Model to study live UPEC infections**	**Isabel Sorg,** University of Basel
31	**Collective behavior of an opportunistic pathogen promotes colonization and breaching of the human respiratory epithelial barrier**	**Anna Leoni Swart,** University of Basel
32	**RAMANMETRIXTM & RAMANBIOASSAYTM as a chip-based diagnostic System using Raman spectroscopy**	**Olivia Treuheit**, Biophotonics Diagnostics GmbH
33	**BamA inhibitors to kill Gram-negative pathogens**	**Zerlina Wuisan**, Justus-Liebig-University of Giessen
34	**Prospects of novel bio-antibiotics to inhibit the BAM complex**	**Philippe A. Lehner**, University of Basel

A big thank you to our sponsors!

Sponsors and exhibitors:

Supporting Partners:

Media Partner:

Local Host: